Clinical Trial Update: A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers [Phase 2]

View source ↗

Summary

Phase 2 study evaluating MM-121 (seribantumab) in combination with paclitaxel for platinum-resistant/refractory advanced ovarian, fallopian tube, and primary pe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• MM-121 (seribantumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-05-12